NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Price Target & More

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) issued its earnings results on Friday, March, 2nd. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.04. Eyegate Pharmaceuticals had a negative return on equity of 653.57% and a negative net margin of 2,480.28%. View Eyegate Pharmaceuticals' Earnings History.

1 brokers have issued 1-year price objectives for Eyegate Pharmaceuticals' stock. Their forecasts range from $3.00 to $3.00. On average, they expect Eyegate Pharmaceuticals' stock price to reach $3.00 in the next year. View Analyst Ratings for Eyegate Pharmaceuticals.

Eyegate Pharmaceuticals saw a decline in short interest in the month of April. As of April 30th, there was short interest totalling 980,874 shares, a decline of 40.5% from the April 13th total of 1,647,564 shares. Based on an average daily trading volume, of 2,785,591 shares, the days-to-cover ratio is currently 0.4 days. Approximately 3.6% of the shares of the company are sold short.

Some companies that are related to Eyegate Pharmaceuticals include Forward Pharma (FWP), Ophthotech (OPHT), BioLineRx (BLRX), Columbia Laboratories (JNP), KemPharm (KMPH), KalVista Pharmaceuticals (KALV), Advaxis (ADXS), Galmed Pharmaceuticals (GLMD), Sunesis Pharmaceuticals (SNSS), Cumberland Pharmaceuticals (CPIX), Gemphire Therapeutics (GEMP), Axsome Therapeutics (AXSM), Northwest Biotherapeutics (NWBO), Xenon Pharmaceuticals (XENE) and Novelion Therapeutics (NVLN).

(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

Media headlines about EYEG stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eyegate Pharmaceuticals earned a news impact score of 0.11 on Accern's scale. They also assigned headlines about the specialty pharmaceutical company an impact score of 46.25 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Eyegate Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ARMISTICE CAPITAL, LLC (40.20%), ARMISTICE CAPITAL, LLC (50.80%) and ARMISTICE CAPITAL, LLC (4.99%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Morton Goldberg, Sarah Romano, Stephen From and Ventech Capital Ii. View Institutional Ownership Trends for Eyegate Pharmaceuticals.

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EYEG stock can currently be purchased for approximately $0.63.

Eyegate Pharmaceuticals has a market capitalization of $25.98 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Eyegate Pharmaceuticals employs 17 workers across the globe.

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.